aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Syntheta...
January 22 2021 - 8:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel biological pathways, today announced that it will present a
poster and audio presentation at the upcoming Society for
Laboratory Automation and Screening Digital International
Conference and Exhibition (SLAS) to be held virtually January
25-27, 2021. The abstract and poster are available on the SLAS
website.
The poster describes a mass spectrometry
proteomics-based approach to identify target receptors for two
distinct extracellular tRNA synthetase fragments. The utilization
of this workflow, which included recombinant protein expression,
flow cytometry, and receptor screening in living cells using the
ligand-receptor capture TriCEPS technology, resulted in the
identification of receptor targets for fragments of the tRNA
synthetases AARS and DARS as well as insights into their potential
biological activity in immunology, cancer and fibrosis.
Furthermore, this approach can be applied more broadly to identify
receptor targets of extracellular proteins and other ligands such
as peptides, antibodies or viruses.
Details of the abstract and poster presentation
are as follows:
Title: A mass spectrometry proteomics-based
approach to identify target receptors for novel extracellular tRNA
synthetase fragmentsAuthors: Blythe C. Dillingham,
Jennifer Brasseit, Björn Hegemann, Ann L. Menefee, Justin Rahman,
Zhiwen Xu, Paul Helbling, Leslie A. Nangle, Ryan A. Adams. aTyr
Pharma, San Diego, CA, CSL Behring, Dualsystems
Biotech.Track: Assay Development and Screening
Date: January 25 – 27, 2021
The poster is also available on the aTyr website.
“We are pleased to present our findings
utilizing a novel approach for identifying receptor targets of
extracellular proteins, and for the first time provide insight into
the potential biological function of extracellular tRNA synthetases
AARS and DARS,” said Sanjay S. Shukla, M.D., M.S., President and
Chief Executive Officer of aTyr. “These findings further validate
the relevance of our tRNA synthetase biology platform to important
disease pathways and demonstrate its ability to generate new drug
targets. Identifying receptor targets for these two tRNA
synthetases, which are relevant to immunology, cancer and fibrosis,
will help guide the development of potential new therapies in these
areas of high unmet need.”
About aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
biological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are usually
identified by the use of words such as “anticipates,” “believes,”
“estimates,” “expects,” “intends,” “may,” “plans,” “projects,”
“seeks,” “should,” “will,” and variations of such words or similar
expressions. We intend these forward-looking statements to be
covered by such safe harbor provisions for forward-looking
statements and are making this statement for purposes of complying
with those safe harbor provisions. These forward-looking statements
include statements regarding potential further research and
development activities related to, and potential utility of, the
newly identified receptor targets, the potential therapeutic
benefits and applications of our current and future product
candidates; timelines and plans with respect to certain development
activities (such as the timing of data from clinical trials); and
certain development goals. These forward-looking statements also
reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. Although we believe that our plans, intentions, expectations,
strategies and prospects, as reflected in or suggested by these
forward-looking statements, are reasonable, we can give no
assurance that the plans, intentions, expectations or strategies
will be attained or achieved. All forward-looking statements are
based on estimates and assumptions by our management that, although
we believe to be reasonable, are inherently uncertain. Furthermore,
actual results may differ materially from those described in these
forward-looking statements and will be affected by a variety of
risks and factors that are beyond our control including, without
limitation, uncertainty regarding the COVID-19 pandemic, risks
associated with the discovery, development and regulation of our
product candidates, the risk that we or our partners may cease or
delay preclinical or clinical development activities for any of our
existing or future product candidates for a variety of reasons
(including difficulties or delays in patient enrollment in planned
clinical trials), the possibility that existing collaborations
could be terminated early, and the risk that we may not be able to
raise the additional funding required for our business and product
development plans, as well as those risks set forth in our most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and in our other SEC filings. Except as required by law, we assume
no obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
|
Contact: |
Ashlee Dunston |
Director, Investor Relations and
Corporate Communications |
adunston@atyrpharma.com |
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024